Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2006

View Archived Issues

Preclinical antidementia profile of FK-962

Antiinflammatory activity of a new SSAO/VAP-1 inhibitor

Aromatase a target for non-small cell lung cancer treatment

Oregovomab active in recurrent ovarian cancer

Encouraging results seen with pegylated arginine deiminase in metastatic melanoma

Pharmexa sets out development plans for GV-1001

Nuvelo and Bayer collaborate on alfimeprase

Aradigm seeks orphan drug designation for liposomal ciprofloxacin

Analgesic potential of new analogues of valproic acid

Pivotal phase III study evaluates cethromycin in community-acquired pneumonia

Zonagen receives IRB approval to begin phase III study of Androxal

Sangamo and Pfizer expand research collaboration

CancerVax and Micromet sign merger agreement

Lilly ruled to have breached oral PTH license agreements with Emisphere

Grants support work in diabetic kidney disease at University of Virginia

New therapeutic agents for inflammatory disorders disclosed in recent patents

VivaGel receives fast track status for HIV prevention

Thalomid pivotal multiple myeloma trial reaches prespecified interim endpoint

Bayer reports on the first potent and selective PDE9 inhibitor

Theravance prepares and tests novel beta2-adrenoceptor agonists for asthma

FDA approves quarterly intravenous Boniva for postmenopausal osteoporosis

FDA approval for subcutaneous immunoglobulin treatment Vivaglobin

NDA submission for CARDIOsphere to assess coronary artery disease

Taclonex approved for psoriasis vulgaris

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
HX-16108 holds promise for treating inflammatory skin diseases
BioWorld Science
Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...